Ovarian Suppression Can Help Protect Ovarian Function and May Preserve Fertility in Younger Women Being Treated with Chemotherapy

Preserving fertility after chemotherapy is an important issue for many, many younger women diagnosed with early-stage breast cancer. Dr. Matteo Lambertini, medical oncologist at the Institute Jules Bordet Brussels, presented research at the 2017 San Antonio Breast Cancer Symposium showing that ovarian suppression with a gonadotropin-releasing hormone analogue such as Lupron, Trelstar, or Zoladex, can safely protect ovarian function and may help preserve fertility in younger women being treated with chemotherapy for early-stage disease. Listen to the podcast to hear Dr. Lambertini explain: why earlier studies on this topic had mixed results the results of the study the side effects of gonadotropin-releasing hormone analogues the strategies he recommends to his younger patients diagnosed with early-stage breast cancer who want to have a child after chemotherapy